-
Product Insights
NewVulvar Cancer – Drugs In Development, 2024
Empower your strategies with our Vulvar Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. The Vulvar Cancer drugs in...
-
Product Insights
NewVaginal Cancer – Drugs In Development, 2024
Empower your strategies with our Vaginal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Vaginal cancer is a rare cancer that occurs in the vagina. Symptoms includes watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, and vaginal bleeding. Risk factors include age, smoking, HIV infection, and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy, and chemotherapy. The Vaginal Cancer drugs in development market research report provide comprehensive information...
-
Product Insights
NewPenile Cancer – Drugs In Development, 2024
Empower your strategies with our Penile Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Penile cancer is a rare malignancy that develops on the skin or tissues of the penis. It occurs when normal cells in the penis undergo genetic mutations, leading to uncontrolled growth and the formation of a cancerous tumor. Early stages of penile cancer might not cause noticeable symptoms. As the disease progresses, signs and symptoms may include changes in skin color or...
-
Product Insights
NewRecurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024
Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges....
-
Product Insights
NewOropharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Oropharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Oropharyngeal cancer is a disease in which malignant cells form in the tissue of oropharynx. The oropharynx is the middle part of the throat and includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types: HPV-positive, which are related to human papillomavirus infection; and HPV-negative cancers, which...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy 2 For Oncology And Coronavirus Disease 2019 (COVID-19) in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cellular Immunotherapy 2 For Oncology And Coronavirus Disease 2019 (COVID-19) in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cellular Immunotherapy 2...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Head And Neck Cancer Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Ovarian Cancer Drug Details: TG-4050 is under development for...